Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181763 · ClinicalTrials.gov registry record · Phase 1
Evaluation of MDMA on Startle Response
A Phase 1 study, sponsored by Resilient Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03181763: Completed Phase 1 study, sponsored by Resilient Pharmaceuticals.
NCT03181763 is a Phase 1 study that has completed, run by Resilient Pharmaceuticals. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03181763, a Phase 1 study, has completed, sponsored by Resilient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if MDMA impacts startle response in healthy participants. The main question it aims to answer is: Does MDMA impact participant's performance on a startle test? Researchers will compare healthy volunteers who have taken MDMA to those who have taken placebo. Participants will first undergo a 1-hour startle test. The next day, they will be randomized to receive either MDMA or placebo followed by another startle test and vitals signs and blood measurements. Participants will return the next day for a final startle test. Their sleep will be tracked by a Fitbit device.
Interventions
- DRUG Placebo
- DRUG Midomafetamine
- BEHAVIORAL Acoustic startle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-03-14 |
| Est. Completion | 2020-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03181763
The ClinicalTrials.gov registry entry for NCT03181763 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Resilient Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03181763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03181763 about?
NCT03181763 is a clinical study titled "Evaluation of MDMA on Startle Response". The goal of this clinical trial is to learn if MDMA impacts startle response in healthy participants. The main question it aims to answer is: Does MDMA impact participant's performance on a startle test? Researchers will compare healthy volunteers who have taken MDMA to those who have taken placeb...
What is the current status of trial NCT03181763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-03-14. Estimated completion is 2020-08-01.
What interventions are being tested in trial NCT03181763?
The interventions under investigation include: Placebo (DRUG), Midomafetamine (DRUG), Acoustic startle (BEHAVIORAL).
Who is sponsoring clinical trial NCT03181763?
This trial is sponsored by Resilient Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.